Acumen discovers and develops targeted therapies for the safe and effective treatment of Alzheimer’s disease and related neurodegenerative diseases. Our founders pioneered seminal discoveries and methods to understand the role of toxic amyloid-beta oligomers (Aβo) in synaptic dysfunction and neurodegeneration. These early insights have fostered decades of research on the biology of Aβo at Acumen and throughout the field. We are now on the on cusp of realizing the therapeutic potential of Aβo targeted drugs.
ACU193 Lead Candidate
Acumen and Merck & Co., through an eight-year research collaboration, produced our lead drug candidate, ACU193, for which Acumen holds exclusive rights. Extensive pre-clinical research demonstrates ACU193 selectively targets Aβo with a favorable safety profile and efficacy. We expect to initiate clinical trials for ACU193 in 2020 as the first monoclonal antibody therapeutic that selectively targets Aβo in Alzheimer’s patients.
Venture and NIH Backing
Acumen has recently closed on a $15 million Series A-1 round from PBM Capital Group, Sands Capital Ventures and private investors. The funding will allow us to complete ACU193 CMC and GLP safety testing requirements and obtain an Investigational New Drug Application (IND). The preclinical and early clinical development of ACU193 is also funded through a $3.6 million U01 grant from the National Institute of Aging.